At the news
? BULLISHIMPACT 8/10 DEFA14A filed May 7, 2026 at 09:00 ET
Catalyst Pharmaceuticals has entered into a definitive agreement to be acquired by Angelini Pharma S.p.A. for $31.50 per share in cash, representing a total equity value of approximately $4.1 billion. The transaction, unanimously approved by both boards, is expected to close in Q3 2026 and provides a 28% premium to the 30-day VWAP. Separately, Catalyst resolved all pending FIRDAPSE patent litigation with Hetero, pushing generic entry to no earlier than January 2035.
- Acquisition price of $31.50 per share in cash, total equity value ~$4.1 billion
- 28% premium to 30-day VWAP as of April 22, 2026; 21% premium to unaffected closing price
- Closing expected in Q3 2026, subject to stockholder approval, HSR, and other conditions
- All directors and executive officers entered into voting agreements to support the merger
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access